- Home
- GNLX vs AEI Comparison
GNLX vs AEI Comparison
Compare GNLX & AEI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GNLX | AEI |
|---|---|---|
| Founded | 2001 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Building operators |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 124.8M | 119.4M |
| IPO Year | 2022 | 2019 |
Fundamental Metrics
Financial Performance| Metric | GNLX | AEI |
|---|---|---|
| Price | $2.70 | $2.01 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $19.75 | N/A |
| AVG Volume (30 Days) | ★ 181.8K | 19.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 18.10 | ★ 93.40 |
| EPS | ★ N/A | N/A |
| Revenue | $8,000.00 | ★ $16,238,200.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.99 | $0.70 |
| 52 Week High | $8.54 | $4.55 |
Technical Indicators
Market Signals| Indicator | GNLX | AEI |
|---|---|---|
| Relative Strength Index (RSI) | 45.03 | 33.73 |
| Support Level | $2.31 | $1.13 |
| Resistance Level | $2.80 | $2.76 |
| Average True Range (ATR) | 0.16 | 0.18 |
| MACD | 0.07 | -0.03 |
| Stochastic Oscillator | 51.13 | 4.69 |
Price Performance
Historical ComparisonAbout GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.
About AEI Alset Inc. (TX)
Alset Inc is a diversified holding company engaged through its subsidiaries in the development of EHome communities and other real estate, financial services, digital transformation technologies, biohealth activities, and consumer products with operations in the United States, Singapore, Hong Kong, Australia, and South Korea. The Company operates in four business segments: real estate, digital transformation technology, Biohealth, and other business activities, and it derives a majority of its revenue from the Real Estate segment.